home / stock / prqr / prqr quote
Last: | $1.99 |
---|---|
Change Percent: | -2.15% |
Open: | $1.9 |
Close: | $1.99 |
High: | $2.07 |
Low: | $1.865 |
Volume: | 132,609 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.99 | $1.9 | $1.99 | $2.07 | $1.865 | 132,609 | 04-19-2024 |
$1.86 | $1.94 | $1.86 | $2.05 | $1.81 | 182,726 | 04-18-2024 |
$1.9 | $2 | $1.9 | $2.04 | $1.86 | 197,899 | 04-17-2024 |
$2 | $2 | $2 | $2.07 | $1.91 | 220,021 | 04-16-2024 |
$2.045 | $2.2 | $2.045 | $2.2 | $1.91 | 319,416 | 04-15-2024 |
$2.2 | $2.23 | $2.2 | $2.31 | $2.11 | 132,395 | 04-12-2024 |
$2.3 | $2.29 | $2.3 | $2.31 | $2.25 | 35,674 | 04-11-2024 |
$2.26 | $2.27 | $2.26 | $2.39 | $2.25 | 308,140 | 04-10-2024 |
$2.39 | $2.15 | $2.39 | $2.46 | $2.1478 | 211,362 | 04-09-2024 |
$2.13 | $2.2 | $2.13 | $2.25 | $2.13 | 254,828 | 04-08-2024 |
$2.21 | $2.16 | $2.21 | $2.22 | $2.13 | 85,430 | 04-05-2024 |
$2.18 | $2.12 | $2.18 | $2.2 | $2.115 | 113,430 | 04-04-2024 |
$2.125 | $2.09 | $2.125 | $2.18 | $2.08 | 73,514 | 04-03-2024 |
$2.1 | $2.14 | $2.1 | $2.21 | $2.0501 | 137,323 | 04-02-2024 |
$2.19 | $2.26 | $2.19 | $2.26 | $2.1 | 165,654 | 04-01-2024 |
$2.2899 | $2.41 | $2.2899 | $2.47 | $2.23 | 109,180 | 03-29-2024 |
$2.2899 | $2.41 | $2.2899 | $2.47 | $2.23 | 109,180 | 03-28-2024 |
$2.38 | $2.4 | $2.38 | $2.4363 | $2.36 | 43,391 | 03-27-2024 |
$2.4 | $2.37 | $2.4 | $2.49 | $2.3505 | 47,379 | 03-26-2024 |
$2.39 | $2.46 | $2.39 | $2.49 | $2.36 | 154,773 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully defended against opposition filed against a key pate...
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinic Accelerated development of Axiomer™ for CNS applications via...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against an opposition filed in Japan against a pat...